/Investor DB

Casdin Capital — 2022 Investments

8 investments dated 2022 · listed companies and verified rows first · show all

Leyden Labsleydenlabs.cominSeries B · Jan 2022 · $140M✓ verified

Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.

BiotechDeep TechHealthtechLeiden, NL

Koenraad Wiedhaup(Founder & Chief Executive Officer)inRonald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)inDinko Valerio(Founder and Chair of the Supervisory Board)inJintanat Ananworanich(Chief Medical Officer)inClarissa Koch(Chief Scientific Officer)in

Co-investorsClavystBioF-Prime CapitalGV (Google Ventures)Bluebird VenturesByers CapitalEuropean Innovation Council Fund+7 more

MOMA Therapeuticsmomatx.comin𝕏May 2022 · $150M

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in

Co-investorsLifeSci Venture PartnersNextech InvestThird Rock VenturesAlexandriaCreacion VenturesGoldman Sachs+4 more

ONIoni.bioin𝕏Jan 2022 · $75M

ONI develops the Nanoimager, an automated super-resolution imaging system.

BiotechDeep TechHardwareMedical DevicesOxford, GB

Paul Scagnetti(Chief Executive Officer)in

Co-investorsAnjostARCH Venture PartnersArtis VenturesFuture Planet CapitalOxford Technology ManagementVertical Venture Partners+6 more

Ventus Therapeuticsventustx.cominFeb 2022

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechWaltham, US

Judith Lieberman(Co-Founder)Daniel Koerwer(Executive Officer)inMichael Crackower(Executive Officer)inZachary McNealy(Executive Officer)Marcelo Bigal, M.D., Ph.D.(President and Chief Executive Officer)

BoardJosh Resnick(Director)in

Co-investorsAndreessen HorowitzGV (Google Ventures)RA CapitalSoftBank Vision FundVersant VenturesAlexandria+3 more

Verana Healthveranahealth.comin𝕏Feb 2022 · $150M

Verana Health aggregates de-identified clinical data from a network of over 20,000 physicians in ophthalmology, urology, and neurology to power real-world evidence, clinical trial enablement, and quality reporting for pharmaceutical companies and healthcare providers using AI and machine learning.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechSan Francisco, US

Mark Blumenkranz, MD(Co-Founder, Verana Health and Lagunita Biosciences)Sujay Jadhav(Chief Executive Officer)in

Co-investorsNovo HoldingsBreyer CapitalDeerfield Management CompanyGV (Google Ventures)Merck Global Health Innovation FundMSD Global Health Innovation Fund+7 more

Volta Labs, Inc.voltalabs.comin𝕏Series A · Jan 2022

Volta develops a hardware and software platform for genomics sample preparation that automates the extraction of biological information.

AI & Machine LearningBiotechDeep TechHardwareHealthtechMedical DevicesRoboticsBoston, US

Udayan Umapathi(Founder)inPatrick ShinMagali Soumillon(Senior Director)Will Langford(Product Engineer)Liam Masters(Software Engineer)Niranjan Vissa(Head of Software)

Co-investorsBlindspot Ventures Management CoMana VenturesRising TideSoma CapitalThe E14 FundY Combinator+6 more

Xcell BiosciencesinJan 2022

BiotechSan Francisco, US

Kaz Ohno(Executive Officer)James Lim(Executive Officer)Brian S. Feth(Executive Officer, Director)

BoardSaeid Akhtari(Director)

Co-investorsDynamk CapitalFormic VenturesViking Global Investors

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Standard BioTools

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.